BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Has Consensus Price Target of $20.75

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.38.

A number of analysts have issued reports on BCRX shares. Weiss Ratings cut shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Wedbush dropped their price target on shares of BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, November 5th. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in shares of BioCryst Pharmaceuticals by 231.6% in the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after acquiring an additional 3,556,208 shares during the last quarter. Pacer Advisors Inc. acquired a new position in BioCryst Pharmaceuticals in the first quarter worth about $14,880,000. ADAR1 Capital Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $1,330,000. Wedge Capital Management L L P NC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $3,808,000. Finally, Perceptive Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 135.1% in the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after buying an additional 4,271,504 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.53 on Wednesday. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -5.30 and a beta of 0.55. BioCryst Pharmaceuticals has a 52-week low of $6.23 and a 52-week high of $11.22. The stock has a 50-day simple moving average of $8.38 and a 200-day simple moving average of $8.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 92.91% and a negative net margin of 37.40%. The business had revenue of $180.29 million during the quarter, compared to analysts’ expectations of $165.67 million. During the same quarter in the previous year, the business posted $0.06 EPS. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. As a group, equities research analysts predict that BioCryst Pharmaceuticals will post -2.26 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.